Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments

Bibliography

• Jelkmann W. Erythropoietin after a century of research: younger than ever. Eur J Haematol 2007;78(3):183-205
   PubMed Web of Science ®Google Scholar
• Weise M, Bielsky MC, De Smet K. Biosimilars - why terminology matters. Nat Biotechnol 2011;29:690-3
   PubMed Web of Science ®Google Scholar
• Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011;365(5):385-8
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from: http://www biosimilars ca/docs/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010 pdf 2009
   Google Scholar
• Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2007;19(3):411-9
   PubMed Web of Science ®Google Scholar
• Covic A, Cannata-Andia J, Cancarini G, Biosimilars and biopharmaceuticals: what the nephrologists need to know–a position paper by the ERA-EDTA Council. Nephrol Dial Transplant 2008;23(12):3731-7
   PubMed Web of Science ®Google Scholar
• Schellekens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010;28(1):28-31
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-80
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Recombinant EPO production - points the nephrologist should know. Nephrol Dial Transplant 2007;22(10):2749-53
   PubMed Web of Science ®Google Scholar
• Kawasaki N, Itoh S, Hashii N, The significance of glycosylation analysis in development of biopharmaceuticals. Biol Pharm Bull 2009;32(5):796-800
   PubMed Web of Science ®Google Scholar
• Kramer I. Pharmacy and pharmacology of biosimilars. J Endocrinol Invest 2008;31(5):479-88
   PubMed Web of Science ®Google Scholar
• Locatelli F, Pisoni RL, Combe C, Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19(1):121-32
   PubMed Web of Science ®Google Scholar
• Regidor DL, Kopple JD, Kovesdy CP, Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17(4):1181-91
   PubMed Web of Science ®Google Scholar
• KDOQI, National Kidney Foundation. Am J Kidney Dis 2006;47(5 Suppl 3):S11-S145; Erratum in Am J Kidney Dis 2006; 48(3):518
   PubMed Web of Science ®Google Scholar
• Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009;75(1):15-24
   PubMed Web of Science ®Google Scholar
• Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med 2009;60:181-92
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116(20):4045-59
   PubMed Web of Science ®Google Scholar
• Glaspy J, Crawford J, Vansteenkiste J, Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010;102(2):301-15
   PubMed Web of Science ®Google Scholar
• Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 2008;67:39-61
   PubMed Web of Science ®Google Scholar
• Elliott S, Sinclair AM, Begley CG. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107(3):1892-5
   PubMed Web of Science ®Google Scholar
• Laugsch M, Metzen E, Svensson T, Lack of functional erythropoietin receptors of cancer cell lines. Int J Cancer 2008;122(5):1005-11
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Rogers N, Busse L, Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008;98(6):1059-67
   PubMed Web of Science ®Google Scholar
• Swift S, Ellison AR, Kassner P, Absence of functional EpoR expression in human tumor cell lines. Blood 2010;115(21):4254-63
   PubMed Web of Science ®Google Scholar
• Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009;4(2):186-201
   PubMedGoogle Scholar
• Storring PL, Tiplady RJ, Gaines Das R, Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol 1998;100:79-89
   PubMed Web of Science ®Google Scholar
• Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001;98:3626-34
   PubMed Web of Science ®Google Scholar
• EMA. Assessment report. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001033/human_med_001204.jsp&jsenabled=true
   Google Scholar
• Nimtz M, Wray V, Rudiger A, Conradt HS. Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett 1995;365(2-3):203-8
   PubMed Web of Science ®Google Scholar
• Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84:3-10
   PubMed Web of Science ®Google Scholar
• Elliott S, Lorenzini T, Asher S, Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003;21(4):414-21
   PubMed Web of Science ®Google Scholar
• Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000;20(4):375-81
   PubMed Web of Science ®Google Scholar
• Jarsch M, Brandt M, Lanzendorfer M, Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2007;81(1):63-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ema.europa.eu/
   Google Scholar
• Key C, Mulchchrone B, Wai K. Available from: http://www.quintiles.com/elements/media/inthenews/reviewing-existing-risk-management-plans.pdf. rajpharma com 2010
   Google Scholar
• Schiestl M, Stangler T, Torella C, Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011;29(4):310-12
   PubMed Web of Science ®Google Scholar
• Brinks V, Hawe A, Basmeleh AH, Quality of original and biosimilar epoetin products. Pharm Res 2011;28(2):386-93
   PubMed Web of Science ®Google Scholar
• Deechongkit S, Wen J, Narhi LO, Physical and biophysical effects of polysorbate 20 and 80 on darbepoetin alfa. J Pharm Sci 2009;98(9):3200-17
   PubMed Web of Science ®Google Scholar
• Anonymous. Erythropoietin concentrated solution. Eur Pharmacopoeia 4th Edition2002 (monograph 1316):1123-8
   Google Scholar
• Jelkmann W. Efficacy of recombinant erythropoietins: is there unity of international units? Nephrol Dial Transplant 2009;24:1366-8
   PubMed Web of Science ®Google Scholar
• Brockmeyer C, Seidl A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. Eur J Hosp Pharm 2009;15:34-41
   Google Scholar
• Sorgel F, Thyroff-Friesinger U, Vetter A, Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial. BMC Clin Pharmacol 2009;9:10
   PubMedGoogle Scholar
• Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 2009;72(5):380-90
   PubMed Web of Science ®Google Scholar
• Sorgel F, Thyroff-Friesinger U, Vetter A, Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 2009;83(2):122-30
   PubMed Web of Science ®Google Scholar
• Weigang-Kohler K, Vetter A, Thyroff-Friesinger U. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 2009;32:168-74
   PubMed Web of Science ®Google Scholar
• Schellekens H. Assessing the bioequivalence of biosimilars. The Retacrit case. Drug Discov Today 2009;14(9-10):495-9
   PubMed Web of Science ®Google Scholar
• Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther 2008;25(11):1215-28
   PubMed Web of Science ®Google Scholar
• Krivoshiev S, Todorov VV, Manitius J, Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Curr Med Res Opin 2008;24(5):1407-15
   PubMed Web of Science ®Google Scholar
• Wizemann V, Rutkowski B, Baldamus C, Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin 2008;24(3):625-37
   PubMed Web of Science ®Google Scholar
• Krivoshiev S, Wizemann V, Czekalski S, Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther 2010;27(2):105-17
   PubMed Web of Science ®Google Scholar
• Tzekova V, Mihaylov G, Elezovic I, Koytchev R. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin 2009;25(7):1689-97
   PubMed Web of Science ®Google Scholar
• Porter S. Human immune response to recombinant human proteins. J Pharm Sci 2001;90(1):1-11
   PubMed Web of Science ®Google Scholar
• Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-62
   PubMed Web of Science ®Google Scholar
• Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target 2010;18(7):489-98
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8(3):E501-7
   PubMed Web of Science ®Google Scholar
• Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010;31(2):53-9
   PubMed Web of Science ®Google Scholar
• Scott DW, De Groot AS. Can we prevent immunogenicity of human protein drugs? Ann Rheum Dis 2010;69(Suppl 1):i72-6
   Google Scholar
• Schellekens H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 2008;14:191-202
   PubMedGoogle Scholar
• Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010;116(22):4542-5
   PubMed Web of Science ®Google Scholar
• Rossert J. Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB) Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest 2005;35(Suppl 3):95-9
   PubMedGoogle Scholar
• Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant 2005;20(Suppl 4):3-8; Erratum in Nephrol Dial Transplant 2005; 20(8):1773
   Google Scholar
• Macdougall IC, Roger SD, De Francisco A, Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004;96(3):c88-95
   PubMedGoogle Scholar
• Thorpe R, Swanson SJ. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin Diagn Lab Immunol 2005;12(1):28-39
   PubMedGoogle Scholar
• Shimizu H, Saitoh T, Ota F, Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol 2011;126(2):114-18
   PubMed Web of Science ®Google Scholar
• Casadevall N, Nataf J, Viron B, Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346(7):469-75
   PubMed Web of Science ®Google Scholar
• Bennett CL, Luminari S, Nissenson AR, Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351(14):1403-8
   PubMed Web of Science ®Google Scholar
• Boven K, Stryker S, Knight J, The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005;67(6):2346-53
   PubMed Web of Science ®Google Scholar
• Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. Micelle-associated protein in epoetin formulations: a risk factor for immunogenicity? Pharm Res 2003;20(12):1903-7
   PubMed Web of Science ®Google Scholar
• Villalobos AP, Gunturi SR, Heavner GA. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res 2005;22(7):1186-94
   PubMed Web of Science ®Google Scholar
• Sharma B, Bader F, Templeman T, Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with EPREX. Eur J Hosp Pharm 2004;5:86-91
   Google Scholar
• Haag-Weber M, Eckardt KU, Horl WH, Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-a (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol 2012;77(1):8-17
   PubMed Web of Science ®Google Scholar
• Seidl A, Hainzl O, Richter M, Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 2011; [Epub ahead of print]
   Web of Science ®Google Scholar
• Bee JS, Nelson SA, Freund E, Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 2009;98(9):3290-301
   PubMed Web of Science ®Google Scholar
• Jiang Y, Nashed-Samuel Y, Li C, Tungsten-induced protein aggregation: solution behavior. J Pharm Sci 2009;98(12):4695-710
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Ashenden M. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications. Adv Chronic Kidney Dis 2009;16(2):117-30
   PubMed Web of Science ®Google Scholar
• Perez-Oliva JF, Casanova-Gonzalez M, Garcia-Garcia I, Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. BMC Nephrol 2005;6(1):1-11
   PubMedGoogle Scholar
• Goh BL, Ong LM, Sivanandam S, Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Nephrology (Carlton) 2007;12(5):431-6
   PubMed Web of Science ®Google Scholar
• Kim TE, Kim KP, Kim BH, Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers. Clin Ther 2010;32(11):1968-76
   PubMed Web of Science ®Google Scholar
• Schmidt CA, Ramos AS, da Silva JEP, Avaliacao da atividade e caracterizacao de eritropoietin a humana recombinante em produtos farmaceuticos. Arq Bras Endocrinol Metabol 2003;47:183-9
   Google Scholar
• Schellekens H. Biosimilar epoetins: how similar are they? Eur J Hosp Pharm 2004;3:43-7
   Google Scholar
• Park SS, Park J, Ko J, Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci 2008;98:1688-99
   Web of Science ®Google Scholar
• Yang J, Joo KW, Kim YS, Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies. J Nephrol 2005;18(1):102-5
   PubMed Web of Science ®Google Scholar
• Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int 2008;74:1617-22
   PubMed Web of Science ®Google Scholar
• Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309. Nephrol Dial Transplant 2008;24(5):1545-9
   PubMed Web of Science ®Google Scholar
• Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int 2011;80(1):88-92
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011;86(4):277-88
   PubMed Web of Science ®Google Scholar
• Barosi G, Bosi A, Abbracchio MP, Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96(7):937-42
   PubMed Web of Science ®Google Scholar
• Kromminga A, Schellekens H. Antibodies against erythropoietin and other protein-based therapeutics: an overview. Ann NY Acad Sci 2005;1050:257-65
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Wiecek A, Tucker B, Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients. Clin J Am Soc Nephrol 2011;6(11):2579-86
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Rossert J, Casadevall N, A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009;361(19):1848-55
   PubMed Web of Science ®Google Scholar
• Bouman-Thio E, Franson K, Miller B, A Phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J Clin Pharmacol 2008;48(10):1197-207
   PubMed Web of Science ®Google Scholar
• Sathyanarayana P, Houde E, Marshall D, CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools. Blood 2009;113(20):4955-62
   PubMed Web of Science ®Google Scholar
• Bruegge K, Jelkmann W, Metzen E. Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF- hydroxylases. Curr Med Chem 2007;14:1853-62
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Linde NS, Wynter A, HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood 2007;110(6):2140-7
   PubMed Web of Science ®Google Scholar
• Bernhardt WM, Wiesener MS, Scigalla P, Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21(12):2151-6
   PubMed Web of Science ®Google Scholar
• Available from: http://www.fibrogen.com/press/release/pr_1300378657
   Google Scholar
• Fraisl P, Aragones J, Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 2009;8(2):139-52
   PubMed Web of Science ®Google Scholar
• Nagel S, Talbot NP, Mecinovic J, Therapeutic manipulation of the HIF hydroxylases. Antioxid Redox Signal 2010;12(4):481-501
   PubMed Web of Science ®Google Scholar
• Lippin Y, Dranitzki-Elhalel M, Brill-Almon E, Human erythropoietin gene therapy for patients with chronic renal failure. Blood 2005;106(7):2280-6
   PubMed Web of Science ®Google Scholar
• Available from: http://www faqs org/sec-filings/110225/MEDGENICS-INC_S-1 2011
   Google Scholar